Second-line Therapy for Type 2 Diabetes

被引：0
|
作者：
Krome, Susanne
机构：
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2024年 / 149卷 / 19期
关键词：
D O I：
10.1055/a-2329-7522
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
About 9% of the world's population is affected by type 2 diabetes. The disease is usually progressive and is associated with multiple complications. If metformin fails to effectively lower HbA1c, additive sulfonylureas, SGLT-2 inhibitors and DPP-4 inhibitors are the most commonly used drugs. Randomized studies have mainly compared their benefits with placebo. Target trial emulation enabled direct comparison.
引用
收藏
页码：1127 / 1128
页数：2
相关论文
共 50 条
  • [31] Vascular Events in Patients with Type 2 Diabetes in the Year following Initiation of Second-Line Therapy-The DISCOVER Study
    Kosiborod, Mikhail
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Khunti, Kamlesh
    Pocock, Stuart
    Rathmann, Wolfgang
    Shestakova, Marina V.
    Shimomura, Iichiro
    Surmont, Filip
    Tang, Fengming
    Watada, Hirotaka
    Ji, Linong
    Hammar, Niklas
    DIABETES, 2018, 67
  • [32] Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
    Klarenbach, Scott
    Cameron, Chris
    Singh, Sumeet
    Ur, Ehud
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (16) : E1213 - E1220
  • [33] Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study
    Nicolucci, Antonio
    Chen, Hungta
    Cooper, Andrew
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Ji, Linong
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Medin, Jennie
    Shestakova, Marina, V
    Shimomura, Iichiro
    Tang, Fengming
    Vora, Jiten
    Watada, Hirotaka
    Arnold, Suzanne, V
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 185
  • [34] Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (08) : 773 - 777
  • [35] Global Prevalence of Type 2 Diabetes Complications in 14,391 Patients Initiating Second-Line Therapy: The DISCOVER Study
    Kosiborod, Mikhail
    Arya, Nikita
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Kamal, Samer
    Nicolucci, Antonio
    Pocock, Stuart
    Rathmann, Wolfgang
    Shestakova, Marina V.
    Shimomura, Iichiro
    Tang, Fengming
    Watada, Hirotaka
    Khunti, Kamlesh
    DIABETES, 2017, 66 : A80 - A80
  • [36] EVALUATION OF THE USE, EFFICACY AND SAFETY OF SECOND-LINE AGENTS IN THE TREATMENT OF UNCOMPLICATED TYPE 2 DIABETES
    Adiga, Shalini
    Gill, Rupam
    Varma, Muralidhar
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2017, 13 (04): : E32 - E32
  • [37] Fournier's gangrene in patients with type 2 diabetes using second-line antidiabetic medications
    Petruski-Ivleva, Natalia
    Schneeweiss, Sebastian
    Eapen, Sara
    Rajan, Aditya
    Jan, Saira
    DIABETES OBESITY & METABOLISM, 2020, 22 (02): : 267 - 271
  • [38] Referral to hepatologists or a second-line examination requirement is common in patients with type 2 diabetes mellitus
    Jiang, Wangyan
    Yan, Yongli
    Yuan, Gang
    Du, Tingting
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2024, 34 (05) : 1314 - 1324
  • [39] Diabetes therapy-focus on Asia: second-line therapy debate: insulin/secretagogues
    Eldor, Roy
    Raz, Itamar
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 85 - 89
  • [40] Cost-Effectiveness Analysis of Empagliflozin as a Second-Line Therapy in Treatment Sequences of Patients With Type 2 Diabetes in The United States
    Reifsnider, Odette
    Kansal, Anuraag
    Pimple, Pratik
    Aponte-Ribero, Valerie
    Brand, Sarah
    Shetty, Sharash
    CIRCULATION, 2019, 140
12345